Paper38879802
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
Bumma N and 31 others. J Clin Oncol, 2024. Cited by 165 papers, by iCite.
Cite this record
ConductScience Library. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Papers, record 38879802. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38879802
- Disease
- plasma cell myeloma553 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Clinical Trial, Phase II, Clinical Trial, Phase I, Multicenter Study, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| Antibodies, Bispecific | Major topic |
| Humans | |
| Aged | |
| Male | |
| Female | |
| Middle Aged | |
| Aged, 80 and over | |
| B-Cell Maturation Antigen | |
| Adult | |
| Neoplasm Recurrence, Local |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT03761108 | Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 39405492 | Erratum: Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. | https://conductscience.org/library/papers/39405492 |
Source PubMed
Cited by110
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 165 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42982775 | Impact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma. | Blood Cancer J | 2026 | https://conductscience.org/library/papers/42982775 | PubMed |
| 42980050 | Bispecific antibodies targeting B-cell maturation antigen in multiple myeloma: Current clinical applications, challenges and future directions. | Cancer | 2026 | https://conductscience.org/library/papers/42980050 | PubMed |
| 42959251 | Rethinking immunotherapy sequencing in multiple myeloma: a conceptual adaptive immunotherapy sequencing model. | Front Immunol | 2026 | https://conductscience.org/library/papers/42959251 | PubMed |
| 42921550 | Advancing T Cell Engagers in Multiple Myeloma: Structural Design and Clinical Optimization to Address Current Limitations. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42921550 | PubMed |
| 42882842 | Sequencing BCMA-Directed Therapies in Relapsed/Refractory Multiple Myeloma: A Real-World Comparison of CAR T-Cell Therapy and Bispecific Antibodies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882842 | PubMed |
| 42871283 | Efficacy and specific toxicity profiles of GPRC5D- versus BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: a meta-analysis of clinical trials and real-world studies. | Front Immunol | 2026 | https://conductscience.org/library/papers/42871283 | PubMed |
| 42846987 | Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma. | Hemasphere | 2026 | https://conductscience.org/library/papers/42846987 | PubMed |
| 42844619 | T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis. | J Hematol Oncol | 2026 | https://conductscience.org/library/papers/42844619 | PubMed |
| 42827135 | Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study. | Blood Cancer J | 2026 | https://conductscience.org/library/papers/42827135 | PubMed |
| 42809698 | T-Cell Redirecting Antibodies for the Treatment of Multiple Myeloma: Off-the-Shelf T-Cell Immunity. | Cancer J | 2026 | https://conductscience.org/library/papers/42809698 | PubMed |
| 42786443 | Belantamab mafodotin plus venetoclax in t(11;14)-positive relapsed or refractory multiple myeloma - the BELI(E)VE trial. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42786443 | PubMed |
| 42718550 | Cytomegalovirus infection in patients receiving bispecific antibodies for multiple myeloma and B-cell malignancies: a single-center cohort and meta-analysis. | Front Oncol | 2026 | https://conductscience.org/library/papers/42718550 | PubMed |
| 42699035 | From toxicity to immunity: Evaluating CAR-T and conventional therapies in multiple myeloma through quality-adjusted life year (QALY) outcomes. | Ther Adv Hematol | 2026 | https://conductscience.org/library/papers/42699035 | PubMed |
| 42686747 | T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42686747 | PubMed |
| 42662238 | CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease. | Mol Ther Adv | 2026 | https://conductscience.org/library/papers/42662238 | PubMed |
| 42653183 | T-Cell Engagers Targeting BCMA, GPRC5D, or FcRH5 in Relapsed/Refractory Multiple Myeloma: The Landscape Beyond CAR-T Cell Therapy-A Systematic Review and Network Meta-Analysis. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42653183 | PubMed |
| 42643454 | Safety and efficacy of bispecific antibodies in hematologic neoplasms: a systematic review. | Front Immunol | 2026 | https://conductscience.org/library/papers/42643454 | PubMed |
| 42632850 | Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma. | Blood Cancer J | 2026 | https://conductscience.org/library/papers/42632850 | PubMed |
| 42614483 | Epidemiology and Risk Factors for Infection in Multiple Myeloma Patients Treated With Bispecific Antibodies. | Open Forum Infect Dis | 2026 | https://conductscience.org/library/papers/42614483 | PubMed |
| 42592361 | From T cell engagers to next-generation immune cell engagers for cancer immunotherapy. | Antib Ther | 2026 | https://conductscience.org/library/papers/42592361 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD38 | 952 | PubTator's text mining | https://conductscience.org/library/genes/952 | NCBI Gene |
| SEMA4D | 10507 | PubTator's text mining | https://conductscience.org/library/genes/10507 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| LINVOSELTAMAB | CHEMBL5095373 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL5095373 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38879802
GET https://conductscience.org/api/papers/v1/38879802/authors?page=2